This article is more than 5 years old. Information may no longer be current.
Anti-VEGF effective in wet AMD, diabetic retinopathy
Click Here to Manage Email Alerts
SEATTLE — Patients diagnosed with both neovascular age-related macular degeneration and diabetic retinopathy who received intravitreal injections showed stabilization in best-corrected visual acuity and reduction in central macular thickness, according to a poster presented here.
“Long-term analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilization of BCVA and a reduction in CMT, along with stable or improved DR throughout follow-up,” Lea Querques, MD, said at the Association for Research in Vision and Ophthalmology meeting.
The retrospective study enrolled 41 eyes of 38 patients from four high volume referral centers who had concomitant wet AMD and diabetic retinopathy. Thirteen eyes were administered a mean number of 5.7 injections of Avastin (bevacizumab, Genentech), 35 eyes were administered a mean number of 6.6 injections of Lucentis (ranibizumab, Genentech), eight eyes were administered a mean number of 6.1 injections of Eylea (aflibercept, Regeneron) and one eye was administered 7 injections of Macugen (pegaptanib, Bausch + Lomb).
Median follow-up was 28 months.
Mean BCVA was 0.5 logMAR at baseline and 0.6 logMAR at last follow-up visit (P = .26). Mean central macular thickness was 408 m at baseline and 335 m at the last follow-up visit (P = .032).
No adverse events were reported.
At baseline, 21 eyes were graded on the International Clinical Diabetic Retinopathy Disease Severity Scale as mild nonproliferative diabetic retinopathy (NPDR), 15 eyes as were graded as moderate NPDR, and three eyes were graded as severe NPDR. Two eyes were graded as proliferative diabetic retinopathy that was inactive due to panretinal photocoagulation, Querques said.
During follow-up, one eye was graded as moderate NPDR and one eye as severe NPDR, but it was inactivated due to photocoagulation. – by Nhu Te
Reference:
Querques L. Long-term outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. Presented at: ARVO; May 1-5, 2016; Seattle, Washington.
Disclosure: Querques reported she has no relevant financial disclosures.